Global Lateral Epicondylitis Treatment Market 2019-2023
SKU ID : TNV-14770440 | Publishing Date : 07-Feb-2019 | No. of pages : 119
Detailed TOC of Global Lateral Epicondylitis Treatment Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Non-surgical treatment - Market size and forecast 2018-2023
• Surgical treatment - Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• GlaxoSmithKline plc.
• Johnson & Johnson Services, Inc.
• Merck Sharp & Dohme Corp.
• Pfizer Inc.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Non-surgical treatment - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Non-surgical treatment - Year-over-year growth 2019-2023 (%)
Exhibit 22: Surgical treatment - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Surgical treatment - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Decision framework
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Bayer AG - Vendor overview
Exhibit 50: Bayer AG - Business segments
Exhibit 51: Bayer AG - Organizational developments
Exhibit 52: Bayer AG - Geographic focus
Exhibit 53: Bayer AG - Segment focus
Exhibit 54: Bayer AG - Key offerings
Exhibit 55: Bayer AG - Key customers
Exhibit 56: GlaxoSmithKline plc. - Vendor overview
Exhibit 57: GlaxoSmithKline plc. - Business segments
Exhibit 58: GlaxoSmithKline plc. - Organizational developments
Exhibit 59: GlaxoSmithKline plc. - Geographic focus
Exhibit 60: GlaxoSmithKline plc. - Segment focus
Exhibit 61: GlaxoSmithKline plc. - Key offerings
Exhibit 62: GlaxoSmithKline plc. - Key customers
Exhibit 63: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 64: Johnson & Johnson Services, Inc. - Business segments
Exhibit 65: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 66: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 67: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 68: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 69: Johnson & Johnson Services, Inc. - Key customers
Exhibit 70: Merck Sharp & Dohme Corp. - Vendor overview
Exhibit 71: Merck Sharp & Dohme Corp. - Business segments
Exhibit 72: Merck Sharp & Dohme Corp. - Organizational developments
Exhibit 73: Merck Sharp & Dohme Corp. - Geographic focus
Exhibit 74: Merck Sharp & Dohme Corp. - Segment focus
Exhibit 75: Merck Sharp & Dohme Corp. - Key offerings
Exhibit 76: Merck Sharp & Dohme Corp. - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: List of abbreviations
Keyplayers in Global Lateral Epicondylitis Treatment Market 2019-2023
Bayer AGGlaxoSmithKline plc.
Johnson & Johnson Services Inc.
Merck Sharp & Dohme Corp.
Pfizer Inc.